AMENDMENT

Kindly amend the application, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows.

In the Claims

1. (Currently amended) Compounds of Formula (I)



(I)

wherein

A is a group of the formula $-C(CH_3)=CHR^5$ or $-CH=CHR^5$, wherein R^5 is a heteroaryl- or a heteroarylalkyl group,

U is hydrogen, halogen, C_1-C_4 alkyl, C_3-C_4-cycloalkyl, C_1-C_4 heteroalkyl-,-trifluromethyl or COOH,

G-E is selected from the following groups,



or is part of an optionally substituted phenyl ring,

R^1 is a C_1-C_4-alkyl-, a C_2-C_4-alkenyl-, a C_2-C_4-alkinyl- or a C_3-C_4-cycloalkyl-group,

V-W is a group of formula CH_2CH or CH=C,

X is oxygen or a group of the formula NR^2, wherein R^2 is hydrogen, C_1-C_4 alkyl, C_2-C_4 alkenyl, or C_1-C_4 heteroalkyl,

and

R^3 and R^4 independently from each other represent hydrogen, C_1-C_4-alkyl or together are part of a cycloalkyl group with 3 or 4 ring atoms,
or a pharmacologically acceptable salt~~, solvate, hydrate~~ or formulation thereof.

2. (Cancelled)

3. (Original) Compounds according to claim 1, wherein A is a group of formula (II) or (III)



(II)



(III)

wherein Q is sulphur, oxygen or NR^7, wherein R^7 is hydrogen, C_1-C_4 alkyl or C_1-C_4 heteroalkyl, z is Nitrogen or CH and R^6 is OR^8, NHR^8, C_1-C_4 alkyl, C_2-C_4 alkenyl, C_2-C_4 alkinyl or C_1-C_6 heteroalkyl, wherein R^8 is hydrogen, C_1-C_4 alkyl or C_1-C_4 heteroalkyl.

4. (Previously presented) Compounds according to claim 1, wherein X is oxygen or NH.

5. (Previously presented) Compounds according to claim 1, wherein R^1 is methyl or ethyl.

6. (Previously presented) Compounds according to claim 1, wherein R^3 and R^4 are methyl groups.

7. (Previously presented) Compounds according to claim 1, wherein U is hydrogen, fluorine, methyl, trifluoromethyl or COOH.

8. (Previously presented) Compounds according to claim 1, wherein G-E is selected from the following groups:



9. (Previously presented) Compounds according to claim 1, wherein V-W is CH_2CH.

10. (Currently amended) Pharmaceutical compositions containing a compound[[,]] or a pharmacologically acceptable salt~~, a solvate or a hydrate~~ according to claim 1 or a prodrug of the compound[[,]] and/or the salt~~, the solvate and/or the hydrate~~ and optionally one [[of]] or more carriers and/or one or more adjuvants and/or one or more diluents.

11. (Previously presented) Method of treating a disease selected from the group consisting of breast, ovarian, lung and prostate cancer through administering a pharmaceutically effective amount of a compound or a pharmaceutical composition according to claim 1.

12. (Cancelled)

13. (Previously presented) Compounds of formula (Va) and (Vb),



wherein the groups PG independently from each other represent hydrogen or protecting groups.

14. (Previously presented) A process for preparing a compound of formula (I), comprising reacting a compound according to claim 13 by

a) deprotecting the acid;

b) deprotecting the allyl alcohol;

c) lactonizing the hydroxy acid;

d) deprotecting the remaining alcohols;

e) reducing the disubstituted double bond, if present; and

f) oxidizing the sulfur atom at the 5-position to a sulfoxide.